EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Validation of Interstitial Lung Disease Coding in US Claims Data in Patients with Solid Tumors

Max Shen, Stephanie Wang, Sebastian Schneeweiss, Ann Marie McNeill, Gregory S Calip, Susan Yue, Megan A Clarke, Jun Liu, Neesha Nathwani, Priyanka Anand, Kueiyu Joshua Lin

Clinical Epidemiology · 2026-11 · Volume 18 · 1-12

DOI: 10.2147/clep.s630762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Epidemiology, 2026-11. Verfasst von Max Shen und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The validity of ILD coding in US claims data among patients with cancer remains unclear.

Methods

We conducted a study to test the validity of ILD coding in claims data in patients with lung, breast, ovarian, endometrial, cervical, or colorectal cancer. We used electronic health record (EHR) data from the Mass General Brigham Health Care System linked with Medicare, Medicaid, and commercial claims data from 01/01/2017 to 12/31/2024. The base algorithm required two ICD-10-CM codes for ILD, each 7 to 180 days apart. Several nested algorithms additionally requiring ILD coding by a pulmonologist, ILD-relevant procedure, excluding autoimmune diseases, and requiring chemo/immunotherapy treatment were defined. The positive predictive values (PPVs) of each claims-based algorithm were calculated against the reference standard established through chart review by pulmonologists.

Results

The cohort consisted of 360 patients. PPV of the base algorithm was 59% (95% confidence interval: 53%– 64%). The algorithm additionally requiring ILD-relevant procedure with chemo- or immunotherapy administration and excluding those with autoimmune conditions was 64% (57%– 71%). The PPV of base algorithm among patients with colorectal cancer was the lowest - 38% (24%– 52%). The PPVs improved meaningfully when the index diagnosis of ILD was coded by a pulmonologist, ranging from 78– 88% across different algorithms.

Conclusion

We found that, in patients diagnosed with lung, breast, gynecologic, or colorectal cancer, claims-based ILD diagnoses demonstrated moderate to low alignment with a reference standard by expert chart review. It can be improved when ILD is coded by a pulmonologist, though at the cost of substantially fewer cases of ILD identified. Keywords: interstitial lung disease, breast cancer, lung cancer, ovarian cancer, validation, ICD-10

Zitieren

APA

Shen, M., Wang, S., Schneeweiss, S., McNeill, A. M., Calip, G. S., Yue, S., Clarke, M. A., Liu, J., Nathwani, N., Anand, P., & Lin, K. J. (2026). Validation of Interstitial Lung Disease Coding in US Claims Data in Patients with Solid Tumors. Clinical Epidemiology, Volume 18, 1-12. https://doi.org/10.2147/clep.s630762

Vancouver

Shen M, Wang S, Schneeweiss S, McNeill AM, Calip GS, Yue S, et al. Validation of Interstitial Lung Disease Coding in US Claims Data in Patients with Solid Tumors. Clinical Epidemiology. 2026;Volume 18:1-12. doi:10.2147/clep.s630762

BibTeX
@article{Shen2026,
  author = {Shen, Max and Wang, Stephanie and Schneeweiss, Sebastian and McNeill, Ann Marie and Calip, Gregory S and Yue, Susan and Clarke, Megan A and Liu, Jun and Nathwani, Neesha and Anand, Priyanka and Lin, Kueiyu Joshua},
  title = {Validation of Interstitial Lung Disease Coding in US Claims Data in Patients with Solid Tumors},
  journal = {Clinical Epidemiology},
  year = {2026},
  volume = {Volume 18},
  pages = {1--12},
  doi = {10.2147/clep.s630762}
}
Kostenlos starten →